

# Manjit Dosanjh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7840604/publications.pdf>

Version: 2024-02-01

60  
papers

1,892  
citations

331670

21  
h-index

254184

43  
g-index

61  
all docs

61  
docs citations

61  
times ranked

1698  
citing authors

#	ARTICLE	IF	CITATIONS
1	TIGRE: a MATLAB-GPU toolbox for CBCT image reconstruction. <i>Biomedical Physics and Engineering Express</i> , 2016, 2, 055010.	1.2	170
2	Isolation and characterization of RAD51C, a new human member of the RAD51 family of related genes. <i>Nucleic Acids Research</i> , 1998, 26, 1179-1184.	14.5	152
3	All four known cyclic adducts formed in DNA by the vinyl chloride metabolite chloroacetaldehyde are released by a human DNA glycosylase.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 1024-1028.	7.1	148
4	Benchmarking nuclear models of FLUKA and GEANT4 for carbon ion therapy. <i>Physics in Medicine and Biology</i> , 2010, 55, 5833-5847.	3.0	142
5	The vinyl chloride DNA derivative N2,3-ethenoguanine produces G→A transitions in <i>Escherichia coli</i> .. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 9974-9978.	7.1	130
6	Effect of 3' flanking neighbors on kinetics of pairing of dCTP or dTTP opposite O6-methylguanine in a defined primed oligonucleotide when <i>Escherichia coli</i> DNA polymerase I is used.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989, 86, 8271-8274.	7.1	110
7	Both purified human 1,N6-ethenoadenine-binding protein and purified human 3-methyladenine-DNA glycosylase act on 1,N6-ethenoadenine and 3-methyladenine.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 9386-9390.	7.1	106
8	1,N6-Ethenoadenine Is Preferred over 3-Methyladenine as Substrate by a Cloned Human N-Methylpurine-DNA Glycosylase (3-Methyladenine-DNA Glycosylase). <i>Biochemistry</i> , 1994, 33, 1624-1628.	2.5	87
9	Kinetics of extension of O6-methylguanine paired with cytosine or thymine in defined oligonucleotide sequences. <i>Biochemistry</i> , 1991, 30, 11595-11599.	2.5	73
10	Comparative mutagenesis of O6-methylguanine and O4-methylthymine in <i>Escherichia coli</i> . <i>Biochemistry</i> , 1991, 30, 7027-7033.	2.5	64
11	Suppression of apoptosis by overexpression of Bcl-2 or Bcl-xL promotes survival and mutagenesis after oxidative damage. <i>Biochimie</i> , 1997, 79, 613-617.	2.6	52
12	Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial. <i>BMC Cancer</i> , 2012, 12, 137.	2.6	46
13	Site-directed mutagenesis for quantitation of base-base interactions at defined sites. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1990, 233, 45-51.	1.0	45
14	Investigating the robustness of ion beam therapy treatment plans to uncertainties in biological treatment parameters. <i>Physics in Medicine and Biology</i> , 2012, 57, 7983-8004.	3.0	43
15	Comparative efficiency of forming m4T.cntdot.G versus m4T.cntdot.A base pairs at a unique site by use of <i>Escherichia coli</i> DNA polymerase I (Klenow fragment) and <i>Drosophila melanogaster</i> polymerase .alpha.-primase complex. <i>Biochemistry</i> , 1990, 29, 4698-4703.	2.5	42
16	A Monte Carlo-based treatment-planning tool for ion beam therapy. <i>Journal of Radiation Research</i> , 2013, 54, i77-i81.	1.6	40
17	Human cells contain protein specifically binding to a single 1,N6-ethenoadenine in a DNA fragment.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 6839-6842.	7.1	38
18	Both O4-methylthymine and O4-ethylthymine preferentially form alkyl T.G pairs that do not block in vitro replication in a defined sequence. <i>Carcinogenesis</i> , 1993, 14, 1915-1919.	2.8	29

#	ARTICLE	IF	CITATIONS
19	A community call for a dedicated radiobiological research facility to support particle beam cancer therapy. <i>Radiotherapy and Oncology</i> , 2012, 105, 1-3.	0.6	28
20	ENLIGHT: European network for Light ion hadron therapy. <i>Radiotherapy and Oncology</i> , 2018, 128, 76-82.	0.6	23
21	Overview of research and therapy facilities for radiobiological experimental work in particle therapy. Report from the European Particle Therapy Network radiobiology group. <i>Radiotherapy and Oncology</i> , 2018, 128, 14-18.	0.6	21
22	Evidence from in vitro replication that O6-methylguanine can adopt multiple conformations.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 3983-3987.	7.1	19
23	FLUKA simulations of the response of tissue-equivalent proportional counters to ion beams for applications in hadron therapy and space. <i>Physics in Medicine and Biology</i> , 2011, 56, 6545-6561.	3.0	19
24	Arbitrarily large tomography with iterative algorithms on multiple GPUs using the TIGRE toolbox. <i>Journal of Parallel and Distributed Computing</i> , 2020, 146, 52-63.	4.1	19
25	Status of hadron therapy in Europe and the role of ENLIGHT. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2007, 571, 191-194.	1.6	17
26	A possible biomedical facility at the European Organization for Nuclear Research (CERN). <i>British Journal of Radiology</i> , 2013, 86, 20120660.	2.2	15
27	Surveying the Challenges to Improve Linear Accelerator-based Radiation Therapy in Africa: a Unique Collaborative Platform of All 28 African Countries Offering Such Treatment. <i>Clinical Oncology</i> , 2021, 33, e521-e529.	1.4	15
28	ENLIGHT and other EU-funded projects in hadron therapy. <i>British Journal of Radiology</i> , 2010, 83, 811-813.	2.2	14
29	Simulations of microdosimetric quantities with the Monte Carlo code FLUKA for carbon ions at therapeutic energies. <i>International Journal of Radiation Biology</i> , 2012, 88, 176-182.	1.8	14
30	Accurate, Precision Radiation Medicine: A Meta-Strategy for Impacting Cancer Care, Global Health, and Nuclear Policy and Mitigating Radiation Injury From Necessary Medical Use, Space Exploration, and Potential Terrorism. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 250-253.	0.8	13
31	Connection of European particle therapy centers and generation of a common particle database system within the European ULICE-framework. <i>Radiation Oncology</i> , 2012, 7, 115.	2.7	11
32	Developing Innovative, Robust and Affordable Medical Linear Accelerators for Challenging Environments. <i>Clinical Oncology</i> , 2019, 31, 352-355.	1.4	11
33	MODULATION OF PROTO-ONCOGENE EXPRESSION BY POLYCHLORINATED BIPHENYLS IN 3T3-L1 CELL LINE. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 1998, 55, 121-131.	2.3	10
34	A general method for motion compensation in x-ray computed tomography. <i>Physics in Medicine and Biology</i> , 2017, 62, 6532-6549.	3.0	10
35	Synthesis and properties of oligonucleotides containing the mutagenic base O4-benzylthymidine. <i>Bioorganic and Medicinal Chemistry</i> , 1995, 3, 101-108.	3.0	9
36	Metabolism Of Benzo[ <i>a</i> ]Pyrene in Fish Hepatocytes Cultured on Microplates. <i>Polycyclic Aromatic Compounds</i> , 1996, 11, 91-98.	2.6	8

#	ARTICLE	IF	CITATIONS
37	Overcoming Challenges in Providing Radiation Therapy to Patients With Cancer in Nigeria and Experience in the National Hospital Abuja, Nigeria. <i>JCO Global Oncology</i> , 2020, 6, 1232-1236.	1.8	8
38	Monte Carlo Calculations Supporting Patient Plan Verification in Proton Therapy. <i>Frontiers in Oncology</i> , 2016, 6, 62.	2.8	7
39	ENLIGHT. <i>Health Physics</i> , 2012, 103, 674-680.	0.5	6
40	Data-driven Markov models and their application in the evaluation of adverse events in radiotherapy. <i>Journal of Radiation Research</i> , 2013, 54, i49-i55.	1.6	6
41	Feasibility study for a biomedical experimental facility based on LEIR at CERN. <i>Journal of Radiation Research</i> , 2013, 54, i162-i167.	1.6	6
42	Introduction to the EC's Marie Curie Initial Training Network (MC-ITN) project: Particle Training Network for European Radiotherapy (PARTNER). <i>Journal of Radiation Research</i> , 2013, 54, i1-i5.	1.6	6
43	Medical Applications at CERN and the ENLIGHT Network. <i>Frontiers in Oncology</i> , 2016, 6, 9.	2.8	6
44	Union of light ion therapy centers in Europe (ULICE EC FP7) – Objectives and achievements of joint research activities. <i>Radiotherapy and Oncology</i> , 2018, 128, 83-100.	0.6	6
45	South East European International Institute for Sustainable Technologies (SEEIIST). <i>Frontiers in Physics</i> , 2021, 8, .	2.1	6
46	Development of a new photo-detector readout technique for PET and CT imaging. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2007, 571, 329-332.	1.6	5
47	ENLIGHT and LEIR biomedical facility. <i>Physica Medica</i> , 2014, 30, 544-550.	0.7	5
48	Achieving flexible competence: bridging the investment dichotomy between infectious diseases and cancer. <i>BMJ Global Health</i> , 2020, 5, e003252.	4.7	4
49	Patients With Cancer in the Countries of South-East Europe (the Balkans) Region and Prospective of the Particle Therapy Center: South-East European International Institute for Sustainable Technologies (SEEIIST). <i>Advances in Radiation Oncology</i> , 2021, 6, 100772.	1.2	4
50	Introduction to the EC's Marie Curie Initial Training Network Project: The European Training Network in Digital Medical Imaging for Radiotherapy (ENTERVISION). <i>Frontiers in Oncology</i> , 2015, 5, 265.	2.8	2
51	Capturing Acquired Wisdom, Enabling Healthful Aging, and Building Multinational Partnerships Through Senior Global Health Mentorship. <i>Global Health, Science and Practice</i> , 2020, 8, 626-637.	1.7	2
52	Synthesis of a 25 base oligonucleotide containing a styrene oxide modification at the O6 position of 2'-deoxyguanosine at a defined site and incorporation studies of the similarly modified 2'-deoxyguanosine-5'-triphosphate. <i>Carcinogenesis</i> , 1994, 15, 1371-1375.	2.8	1
53	Development of Hadron Therapy for Cancer Treatment in Europe. <i>AIP Conference Proceedings</i> , 2008, .	0.4	1
54	Hadron therapy information sharing prototype. <i>Journal of Radiation Research</i> , 2013, 54, i56-i60.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Availability of technology for managing cancer patients in the Southeast European (SEE) region. Clinical and Translational Radiation Oncology, 2022, 34, 57-66.	1.7	1
56	An analytical model of tumour response to radiotherapy to investigate biological parameters of chordoma treated by X-rays, protons and carbon ions. Physica Medica, 2016, 32, 254.	0.7	0
57	Effective Global Cancer Care Requires Radiation Therapy: Defining a Path From No Radiotherapy to Radiotherapy of High Quality Globally. Journal of Global Oncology, 2017, 3, 16s-16s.	0.5	0
58	Role of Multidisciplinary Collaborative Network for Advancing Cancer Therapy. , 2018, , 107-113.		0
59	Abstract D066: A prospective study on chemotherapy-induced anemia using serial hemoglobin measurement in cancer patients undergoing treatment at National Hospital Abuja, Nigeria. , 2020, , .		0
60	CANCER IN THE COUNTRIES OF THE SEE (BALKANS) REGION AND THE FUTURE PARTICLE THERAPY CENTER â€œ SEEIIST. , 0, , .		0